Clinical trials: Locally Advanced Head and Neck Carcinoma
Locally Advanced Basal Cell Carcinoma, Skin Cancer
Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma
Chemotherapy, radiation therapy, and surgery are standard treatments for basal cell carcinoma at most institutions. The purpose of this study is to determine whether adding vismodegib to radiation (chemoradiotherapy) is safe and…
- Conditions
- Locally Advanced Basal Cell Carcinoma, Skin Cancer, Cutaneous Malignancy
- Trial name
- NCT01835626
- Testing
- Vismodegib, Radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Sue Yom
Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy
Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC
This is a single-center, single-arm, phase II clinical study to evaluate the efficacy and safety of PD-1 inhibitor combined with cetuximab in neoadjuvant therapy for locally advanced HNSCC.
- Trial name
- PC-1 (NCT05993858)
- Testing
- 3cycles (Toripalimab + cetuximab), Surgery, Radiotherapy or chemoradiotherapy
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Salivary Gland Dysfunction, Xerostomia
Everolimus in Restoring Salivary Gland Function in Participants With Locally Advanced Head and Neck Cancer Treated With Radiation Therapy
This early phase 1 trial studies the use of everolimus in restoring salivary gland function in participants with locally advanced head and neck cancer after concurrent chemoradiation or radiation therapy alone.
- Conditions
- Salivary Gland Dysfunction, Xerostomia, Head and Neck Cancer
- Trial name
- NCT03578432
- Testing
- Everolimus, Laboratory Biomarker Analysis, Survey Administration
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Arizona
Lung Cancer Metastatic, Renal Cell Carcinoma
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
Immunotherapy (IO), such as treatment with anti-PD-1, PD-L1, or CTLA-4 inhibitors, is a rapidly expanding treatment for multiple metastatic cancers with improved survival for certain cancers.
- Conditions
- Lung Cancer Metastatic, Renal Cell Carcinoma, Head and Neck Cancer, Triple Negative Breast Cancer
- Trial name
- MOIO (NCT05078047)
- Testing
- Reduced dose intensity of IO
- Where
- 33 sites in France
- Volunteers
- 646 people
- Sponsor
- UNICANCER
Metastatic Cancer, Solid Tumor
Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies
The primary purpose of this study is to see if Sym024 is safe and tolerable as monotherapy and in combination with Sym021 in patients with solid tumor malignancies.
- Trial name
- NCT04672434
- Testing
- Sym021, Sym024
- Where
- 4 sites in United States, Canada
- Volunteers
- 48 people
- Sponsor
- Symphogen A/S
Esophageal Cancer
Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC
SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody. This is an openlabel，single center ，non-randomized ，Single Arm Exploratory Study . This clinical study is an investigator-initiated clinical trial（IIT).
- Trial name
- NCT03671265
- Testing
- SHR-1210, IMRT or VMAT, Apatinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Squamous Cell Carcinoma of Head and Neck
Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas
The goal of this clinical trial is to learn if drug CADI-05, when used together with pembrolizumab (an FDA approved immunotherapy), can help treat locally advanced head and neck squamous cell carcinoma (LA-HNSCC) in adults.
- Trial name
- NCT07455032
- Testing
- intradermal injection of CADI-05, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Fox Chase Cancer Center
Nasopharyngeal Carcinoma (NPC)
Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma
The aim of this study is to evaluate the efficacy, adverse reactions, nutritional status analysis, and quality of life analysis of Toripalimab Plus Induction Chemotherapy Followed by Radiation Therapy Combined with Omega-3 in the…
- Trial name
- NCT07136519
- Testing
- Toripalimab, Omega-3, radiotherapy
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Affiliated Hospital of Guangdong Medical University
Ovary Cancer, Cervix Cancer
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
The purpose of the trial is to establish the tolerability of HuMax-TF-ADC in a mixed population of patients with specified solid tumors.
- Conditions
- Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer
- Trial name
- NCT02001623
- Testing
- Tisotumab Vedotin (HuMax-TF-ADC)
- Where
- 29 sites in United States, Belgium and 3 more
- Volunteers
- 195 people
- Sponsor
- Seagen Inc.
Head and Neck Squamous Carcinoma
Neoadjuvant SBRT in Localized Advanced HNSCC
The response rate of HNSCC to immune checkpoint blockade was not satisfied. Improving the mPR rate of neoadjuvant immunotherapy through the combination with other treatment methods is an important way to further improve the…
- Trial name
- NCT06306846
- Testing
- SBRT+immunochemotherpy, Immunochemotherapy, cetuximab+immunochemotharpy
- Where
- China
- Volunteers
- 81 people
- Sponsor
- Jiang Feng
Radiotherapy; Complications
Hypofractionated Radiotherapy and Concurrent Cisplatin for Head and Neck Cancer
The aim of this study is to evaluate the feasibility of hypofractionated radiation therapy and concomitant chemotherapy with cisplatin for locally advanced head and neck cancer in a high volume brazilian center.
- Trial name
- HIPOCP (NCT03194061)
- Testing
- Hypofractionated Radiotherapy, Weekly cisplatin
- Volunteers
- 20 people
- Sponsor
- Barretos Cancer Hospital
Head and Neck Squamous Cell Carcinoma, Locally Advanced Stage
Molecular-Based Selection of Patients with Head and Neck Squamous Cell Carcinoma: Biomarker Analysis
This is an observational, prospective study enrolling patients who meet the inclusion criteria and provide consent for the use of biopsy samples collected as part of standard clinical practice.
- Trial name
- NCT06905145
- Testing
- Biomarkers evaluation
- Where
- Italy
- Volunteers
- 128 people
- Sponsor
- National Cancer Institute, Naples
Thyroid Cancer
Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer
The purpose of this open label, two stage, phase II study is to evaluate the efficacy and tolerability of ZD6474 in patients with locally advanced or metastatic hereditary medullary thyroid carcinoma.
- Trial name
- NCT00098345
- Testing
- ZD6474 (vandetanib)
- Where
- 6 sites in United States, France
- Volunteers
- 40 people
- Sponsor
- Genzyme, a Sanofi Company
Laryngeal Cancer, Hypopharynx Cancer
SBRT Followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Larynx Preservation in Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx
This trial aims to evaluate the safety and efficiency of SBRT followed by Chemoimmunotherapy of Toripalimab Plus Docetaxel and Cisplatin for Patients with Locally Regionally Advanced Squamous Cell Carcinoma of the Larynx and…
- Trial name
- NCT06611137
- Testing
- SBRT+Toripalimab Plus Docetaxel and Cisplatin
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Sun Yat-sen University
Squamous Cell Carcinoma of the Head and Neck, Human Papilloma Virus
Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study
In this research study, the investigators are studying whether a reduced dose of radiation when given with standard doses of chemotherapy can reduce side effects without compromising control of the cancer.
- Trial name
- NCT01221753
- Testing
- docetaxel, cisplatin, 5-FU
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Dana-Farber Cancer Institute
Larynx, Lip, Oral Cavity and Pharynx
Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck Cancer
This pilot clinical trial studies the side effects of nivolumab, ipilimumab and radiation therapy in treating patients with stage IVA-B head and neck cancer.
- Trial name
- NCT03162731
- Testing
- Nivolumab, Ipilimumab, Simultaneous-Integrated Boost Intensity-Modulated Radiation Therapy
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
HEAD AND NECK CANCER
Accelerated Fractionation Radiotherapy (AFRT) Versus Concurrent Chemoradiotherapy (Crt) In Locally Advanced Head And Neck Squamous Cell Carcinoma
The aim of this trial is to compare the accelerated fractionation radiotherapy and concurrent chemo-radiotherapy in locally advanced head and neck squamous cell carcinoma patients in terms of loco-regional control, toxicities and…
- Trial name
- NCT01291095
- Testing
- CISPLATIN, EXTERNAL BEAM RADIOTHERAPY
- Where
- India
- Volunteers
- 80 people
- Sponsor
- All India Institute of Medical Sciences
Esophageal Cancer
Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
RATIONALE: Drugs used in chemotherapy such as paclitaxel, fluorouracil, and cisplatin use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00069953
- Testing
- filgrastim, pegfilgrastim, cisplatin
- Where
- 97 sites in United States
- Volunteers
- 43 people
- Sponsor
- Radiation Therapy Oncology Group
Advanced Solid Tumors
A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors
The purpose of this study is to evaluate the tolerability and safety profile of ASP1948 when administered as a single agent and in combination with nivolumab or pembrolizumab in participants with locally advanced (unresectable)…
- Trial name
- NCT03565445
- Testing
- ASP1948, nivolumab, pembrolizumab
- Where
- 42 sites in United States, Canada and 7 more
- Volunteers
- 190 people
- Sponsor
- Astellas Pharma Global Development, Inc.
NSCLC, Breast Cancer
A Study of YL202 in Selected Patients With Advanced Solid Tumors
This study is a multicenter, open-label, phase II study of YL202 in China to evaluate the efficacy, safety, and PK characteristics of YL202 in the following selected patients with advanced solid tumors.
- Conditions
- NSCLC, Breast Cancer, HNSCC, Locally Advanced or Metastatic Solid Tumors
- Trial name
- NCT06107686
- Testing
- YL202 should be intravenously infused
- Where
- 82 sites in China
- Volunteers
- 200 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.